Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A multicenter study of posttransplant low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
Blood Adv 2024 Jan 03;[EPub Ahead of Print], L Metheny, RM Sobecks, C Cho, P Fu, S Margevicius, J Wang, L Ciarrone, S Kopp, R Convents, NS Majhail, PF Caimi, F Otegbeye, BW Cooper, MM Gallogly, E Malek, BK Tomlinson, AT Gerds, BK Hamilton, SA Giralt, MA Perales, M de LimaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.